[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507699":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":22,"centralContacts":39,"locations":50,"responsibleParty":82,"collaborators":22,"id":84,"slug":85,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":86,"sex":92,"minAge":22,"maxAge":93,"enrollmentInfo":94,"targetDuration":22,"studyType":97,"phases":98,"briefSummary":10,"conditions":100,"keywords":22,"overallStatus":53,"whyStopped":22,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Gustave Roussy, Cancer Campus, Grand Paris","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Immune organoids from pediatric patient tissues using iPSC","To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)",[12,13,14,15,16],"Procedure: Skin biopsy","Procedure: Fresh tumor sample","Biological: Blood sample","Procedure: Healthy tissue from the tumor","Procedure: Spinal cerebrospinal fluid (SCF)",[18,23,26,31,35],{"type":19,"name":20,"description":20,"armGroupLabels":21,"otherNames":22},"PROCEDURE","Skin biopsy",[9],null,{"type":19,"name":24,"description":24,"armGroupLabels":25,"otherNames":22},"Fresh tumor sample",[9],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":22},"BIOLOGICAL","Blood sample","Blood sample in heparin tubes (highly recommended), to be collected before starting treatment or as soon as hematological recovery has been reached",[9],{"type":19,"name":32,"description":33,"armGroupLabels":34,"otherNames":22},"Healthy tissue from the tumor","Healthy tissue from the tumor site whenever possible",[9],{"type":19,"name":36,"description":37,"armGroupLabels":38,"otherNames":22},"Spinal cerebrospinal fluid (SCF)","Spinal cerebrospinal fluid (SCF) whenever possible",[9],[40,45],{"name":41,"role":42,"phone":43,"phoneExt":22,"email":44},"Claudia PASQUALINI, MD","CONTACT","+33 (0)1 42 11 55 31","claudia.pasqualini@gustaveroussy.fr",{"name":46,"role":42,"phone":47,"phoneExt":48,"email":49},"Jérémy MIONE, MS","+33 (0)1 42 11 42 11","38 61","jeremy.mione@gustaveroussy.fr",[51,67],{"facility":52,"status":53,"city":54,"state":22,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Gustave Roussy","RECRUITING","Villejuif","94805","France","FR",{"type":59,"coordinates":60},"Point",[61,62],2.35992,48.7939,{"lat":62,"lon":61},[65],{"name":66,"role":42,"phone":43,"phoneExt":22,"email":44},"Claudia PASQUALINI",{"facility":68,"status":53,"city":69,"state":70,"zip":71,"country":56,"countryCode":57,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Hopital Necker","Paris","Île-de-France Region","75015",{"type":59,"coordinates":73},[74,75],2.3488,48.85341,{"lat":75,"lon":74},[78],{"name":79,"role":42,"phone":80,"phoneExt":22,"email":81},"Kevin BECCARIA","+33 1 71 19 63 40","kevin.beccaria@aphp.fr",{"type":83,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100507699","engineering-immune-organoids-to-study-pediatric-cancer-100507699",false,"NCT05890781","Engineering Immune Organoids to Study Pediatric Cancer","Engineering Immune Organoids to Study Pediatric Cancer (IMMUNE-ORGANOIDS)","IMMUNEORGANOID","Inclusion Criteria:\n\n* Age at diagnosis ≤ 25 years except for patients with malignant gliomas and renal tumors for whom no upper age limit is applied\n* Medical suspicion or diagnosis of one of the following diseases, regardless of stage:\n* Brain tumors\n* Renal tumors\n* Neuroblastoma\n* Sarcomas\n* Adult patient or parents or guardians should understand, sign and date the appropriate written informed consent from prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.\n* Affiliated to a social security system or beneficiary of the same.\n\nExclusion Criteria:\n\n* Any histology not mentioned in the inclusion criteria\n* Adult patient or parents\u002Fguardians incapable\u002Fincapable of giving its\u002Ftheir consent\n* Patients deprived of their liberty by a judicial or administrative decision","ALL","25 Years",{"count":95,"type":96},108,"ESTIMATED","INTERVENTIONAL",[99],"NA",[101,102,103,104],"Brain Tumor","Kidney Tumor","Neuroblastoma","Sarcoma","2026-02-05",{"date":107,"type":108},"2026-02-09","ACTUAL",{"date":110,"type":108},"2023-05-12",{"date":112,"type":96},"2028-05",{"name":5,"class":6},2]